ImmunoTrend

[Habitual]

http://www.onclive.com/web-exclusives/emerging-immunotherapy-target-in-spotlight-at-wistar

[Habitual]

http://www.news-medical.net/news/20150530/Inhibitors-BGB324-and-BGB10C9-show-promise-in-multiple-murine-models-of-pancreatic-cancer.aspx

[Habitual]

Use of Autoantigen-Loaded Phosphatidylserine-Liposomes to Arrest Autoimmunity in Type 1 Diabetes. http://www.ncbi.nlm.nih.gov/pubmed/26039878?dopt=Abstract

[Habitual]

Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. http://www.ncbi.nlm.nih.gov/pubmed/26055177?dopt=Abstract

[Habitual]

Necrotic Cells Actively Attract Phagocytes through the Collaborative Action of Two Distinct PS-Exposure Mechanisms. http://www.ncbi.nlm.nih.gov/pubmed/26061275?dopt=Abstract

[Habitual]

Unquenchable Surface Potential Dramatically Enhances Cu(2+) Binding to Phosphatidylserine Lipids. http://www.ncbi.nlm.nih.gov/pubmed/26065920?dopt=Abstract

[Habitual]

FDA Approves First Immunotherapy for Children With Cancer

http://blog.aacr.org/fda-approval-dinutuximab/

[Habitual]

Non-small cell lung cancer (NSCLC) is characterized by dramatic changes in phospholipid profiles.

Marien E1, Meister M, Muley T, Fieuws S, Bordel S, Derua R, Spraggins J, Van de Plas R, Dehairs J, Wouters J, Bagadi M, Dienemann H, Thomas M, Schnabel PA, Caprioli RM, Waelkens E, Swinnen JV.



Author information



Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death globally. In order to develop better diagnostics and more effective treatments, research in the past decades has focused on identification of molecular changes in the genome, transcriptome, proteome, and more recently also the metabolome. Phospholipids, which nevertheless play a central role in cell functioning, remain poorly explored. Here, using a mass spectrometry (MS)-based phospholipidomics approach, we profiled 179 phospholipid species in malignant and matched non-malignant lung tissue of 162 NSCLC patients (73 in a discovery cohort and 89 in a validation cohort). We identified 91 phospholipid species that were differentially expressed in cancer versus non-malignant tissues. Most prominent changes included a decrease in sphingomyelins (SMs) and an increase in specific phosphatidylinositols (PIs). Also a decrease in multiple phosphatidylserines (PSs) was observed, along with an increase in several phosphatidylethanolamine (PE) and phosphatidylcholine (PC) species, particularly those with 40 or 42 carbon atoms in both fatty acyl chains together. 2D-imaging MS of the most differentially expressed phospholipids confirmed their differential abundance in cancer cells. We identified lipid markers that can discriminate tumor versus normal tissue and different NSCLC subtypes with an AUC (area under the ROC curve) of 0.999 and 0.885, respectively. In conclusion, using both shotgun and 2D-imaging lipidomics analysis, we uncovered a hitherto unrecognized alteration in phospholipid profiles in NSCLC. These changes may have important biological implications and may have significant potential for biomarker development.

[Habitual]

Curis will be developing small-molecule compounds that can be administered via a pill, rather than nearly all other immune-oncology drugs, which typically must be injected or infused.


http://m.bizjournals.com/boston/blog/bioflash/2015/01/curis-aims-for-anti-cancer-drugs-that-use-the.html?r=full

[Habitual]

This board was started to advance discussions regarding company's developing therapies in the immuno space.
this board will serve as a place for exchanging thoughts, ideas and information as seen through the eyes of an honest ambassador. Company vitals good and bad- Science good and incomplete, both positive and skeptical are real discussions, but constant attacks of any company will not be deemed relative.
as most of you will notice, this board was not categorized under Bio for the simple reason of keeping the community hidden. lets keep this a peaceful and painfully honest community.

Enjoy